SHR-1905

SHR-1905 is a long-acting anti-TSLP monoclonal antibody with a dual-sponsor structure that most summaries miss: Shanghai Hengrui owns Greater China rights and GSK owns ex-China rights after acquiring Aiolos Bio for $1B upfront plus $400M in milestones in February 2024 [9][10]. The lead Phase 2 in severe uncontrolled asthma (NCT05593250, n=260) is completed in China with topline due around late 2026, and GSK is running the Western dose-finding Phase 2 (NCT06748053, n=307, same molecule under the code GSK5784283) [1][8]. The commercial thesis is dosing interval: Phase 1 PK showed a serum half-life of about 80 days, supporting a potential every-six-month subcutaneous schedule versus tezepelumab's every-four-week regimen [6]. Tezepelumab generated combined global sales of $1.22B in 2024 (Amgen and AstraZeneca), setting a validated commercial anchor for TSLP blockade [2]. If the exacerbation reduction holds, Hengrui and GSK split a potentially best-in-class dosing franchise with three parallel Phase 2 programs across nasal polyps, atopic dermatitis, and adolescent asthma [3][4][5].

Novel compound, never approved anywhere. The lead Phase 2 in severe uncontrolled asthma (NCT05593250) is listed as completed on ClinicalTrials.gov with 260 patients randomized in China [1]. The compound is dual-sponsored: Hengrui holds Greater China rights, and GSK holds ex-China rights via its February 2024 acquisition of Aiolos Bio, which had in-licensed the molecule from Hengrui in August 2023 for $17.5M upfront plus up to $1B in milestones [9][10]. The compound carries three names across the two sponsors: SHR-1905 (Hengrui), AIO-001 (Aiolos), and GSK5784283 (GSK). No US FDA designations yet. The Chinese Phase 2 is almost certainly registration-enabling with China's National Medical Products Administration (NMPA), the domestic regulator whose approvals grant China-market access only. Selling in the US or EU requires separate FDA/EMA-reviewed trials, which is now the GSK program (NCT06748053, n=307 dose-finding in uncontrolled asthma) [8]. A Phase 1 study in healthy volunteers was published in Frontiers in Pharmacology in 2024 and reported a serum half-life of approximately 80 days with doses escalated from 50 to 600 mg subcutaneous, supporting an every-six-month dosing interval [6]. Hengrui has three parallel Phase 2 programs across the TSLP-driven Type 2 inflammation space: chronic rhinosinusitis with nasal polyps (NCT05891483, n=114, completed January 2026, topline not yet publicly disclosed) [3], atopic dermatitis (NCT07211542, n=75, recruiting) [4], and an adolescent asthma PK bridging study (NCT06786455, n=9, completed) [5]. The expected readout window for the main asthma trial sits around late 2026 based on completion status, though Hengrui has not publicly disclosed a specific topline date.

TSLP, thymic stromal lymphopoietin, is an alarmin cytokine. Plain translation: it is a distress signal released by the airway lining when it gets hit by allergens, viruses, pollution, or smoke. Once released, TSLP wakes up dendritic cells and mast cells and sets off the full Type 2 inflammation cascade that drives asthma attacks: eosinophil recruitment, IgE production, mucus hypersecretion, bronchoconstriction. Think of TSLP as the alarm bell at the top of the inflammatory tree. Blocking IL-5 (mepolizumab) or IL-4/IL-13 (dupilumab) silences one branch. Blocking TSLP cuts the alarm itself, which is why anti-TSLP therapy works in both eosinophilic and non-eosinophilic (low-T2) asthma, a hard patient segment where IL-5 and IL-4/13 drugs have narrower labels. The validation case for TSLP is strong. Genetic association studies link TSLP variants to asthma susceptibility. Tezepelumab, the first anti-TSLP mAb, cut annual exacerbations by 56% versus placebo in the NAVIGATOR Phase 3 study and did it across eosinophil strata, which was the proof point that mattered [7]. Open Targets scores TSLP evidence for asthma at 0.736, high for an inflammatory cytokine. The mechanism also extends: TSLP sits upstream in nasal polyp pathology and atopic dermatitis, which is why the parallel Phase 2 programs make biological sense. SHR-1905 is a humanized IgG1 kappa anti-TSLP mAb engineered with half-life extension technology; the differentiation from tezepelumab is not mechanism but pharmacokinetics. For SHR-1905, mechanism is well-validated. The open questions are competitive effect size and execution.

NCT05593250 is a randomized, double-blind, placebo-controlled Phase 2 study in severe uncontrolled asthma, n=260, sponsored by Shanghai Hengrui Pharmaceutical and run in China [1]. Primary endpoint is annual asthma exacerbation rate (AAER), the same endpoint that anchored tezepelumab's registration data, which makes the trial directly benchmarkable against NAVIGATOR's 56% exacerbation reduction [7]. The design is clean on paper: AAER is a hard outcome, placebo control removes the confounding that plagues open-label asthma studies, and 260 patients is adequately powered for a two-arm comparison at a 40%+ effect size. The weaknesses are standard for a Chinese Phase 2. First, no biomarker stratification is disclosed in the public trial record, which means the trial will deliver an average effect across eosinophil levels rather than a label-ready phenotype story. Second, the Phase 1 program only enrolled healthy volunteers, so this Phase 2 is the first efficacy read in actual asthma patients, a bigger risk jump than for sponsors with a Phase 1b patient cohort [6]. The GSK-run Western program (NCT06748053, n=307 dose-finding) is a parallel efficacy readout of the same molecule in a different geography and will land in a similar window [8]. These are not competitors but companion data points: a positive Hengrui readout de-risks the GSK program and vice versa.

Our model estimates a 6% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the central one. SHR-1905 will almost certainly reduce exacerbations: TSLP biology is validated and tezepelumab proved it. The real question is magnitude, specifically whether SHR-1905 can reach the 56% figure that tezepelumab set as the competitive bar [7]. A 30% reduction would be clinically meaningful but commercially mediocre, especially without a biomarker subgroup story to carve out responder patients. On-target safety risk is modest. Tezepelumab's safety profile has been clean through registrational and post-marketing use, so mechanism-based toxicity is not the dominant concern. Off-target risk for a long-acting mAb is immunogenicity: the published Phase 1 reported 15% of SHR-1905-treated subjects positive for anti-drug antibodies with no apparent PK or safety impact, but this can look different in asthma patients than in healthy volunteers [6]. Commercial risk is where the differentiation thesis gets tested. Tezepelumab's US polypeptide patent runs to February 3, 2029, with EU to September 9, 2028, so a second-in-class entrant has a real but shrinking window of brand-name exclusivity to compete against before biosimilars arrive [11]. The differentiation hinges on Q6M dosing versus tezepelumab's Q4W: four injections per year becomes two, a meaningful adherence and payer story if the Phase 2 PK/PD confirms the Phase 1 half-life. If the proposed Q6M schedule does not hold up in patients, the differentiation collapses and SHR-1905 becomes a me-too in a market tezepelumab already owns.

Worth watching, with a specific trigger. The signal is the AAER readout from NCT05593250, due within the next few quarters based on the completed trial status [1]. The headline number to watch: anything above a 50% reduction in annual exacerbations versus placebo makes SHR-1905 credible as a tezepelumab challenger. Anything below 40% weakens the differentiation story and pressures GSK's development economics on the ex-China program. Hengrui and GSK are the players to track, together. The dual-sponsor structure means a positive Hengrui readout accelerates the GSK Phase 2 and strengthens the case for a global registrational Phase 3; a weak Hengrui readout puts pressure on GSK to reassess the $1.4B acquisition thesis [9]. The adjacent Phase 2 reads in nasal polyps and atopic dermatitis matter because they test whether SHR-1905 is a platform asset or a single-indication story [3][4]. The nasal polyp trial (NCT05891483) completed in January 2026; topline is not yet publicly disclosed and should be prioritized when it posts. For English-language access, watch Hengrui's investor relations site (IR filings are published in English), GSK quarterly updates, and ATS International Conference (May 2027) and ERS International Congress (September 2027) as the likely presentation venues. The GSK Phase 2 (NCT06748053) is the other dateline to mark, because it is the ex-China arm of the same molecule and will tell investors whether the Q6M dosing thesis holds in a Western patient population [8].